A Phase 3 interventional study of TAF and Placebo in HIV, HIV Infections and Acquired Immunodeficiency Syndrome, sponsored by Gilead Sciences. Completed at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. tenofovir alafenamide · Acquired Immunodeficiency Syndrome.
Among the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome, this one is the 15th largest by enrollment, is one of 3 that started in 2013, is one of 6 in phase 3, and was the 5th registered.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →1 of the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome is open now, in 1 country. Recruiting first, the newest first:
CAN Community Health · Sites in United States
Ages 18+
By country, each count listing its studies:
tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 8 · Phase 4 5
First in 2011; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 80 across the 21 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 34 finished, 19 (56%) have results posted.
Among the 35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences, this one is the 23rd largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 3, and was the 33rd registered.
Gilead Sciences’s Acquired Immunodeficiency Syndrome studies by the year they started, since 2003.
1 of the studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07476339CAN Community HealthREINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE | 2027-06-17 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 35 in Acquired Immunodeficiency Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of tenofovir alafenamide (TAF) versus placebo, each administered with the existing, failing antiretroviral (ARV) regimen. There are 2 parts to this study: Part 1 and Part 2.
Part 1 consists of 2 cohorts, starting with a sentinel cohort, in which participants will be enrolled to receive open-label TAF in addition to their current failing ARV regimen. This cohort will then be followed by a randomized, double-blind, cohort to compare the addition of TAF or placebo in HIV-1 positive adults who are failing their current ARV regimen.
In Part 2, all participants who complete Part 1 of the study will discontinue their failing ARV regimen and TAF or placebo for a 14-day washout period. Following the washout period, all participants who received TAF in Part 1 and have a > 0.5 log10 decline in HIV-1 RNA will receive elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single-tablet regimen (STR) plus atazanavir (ATV) once daily for 48 weeks. Participants who received TAF who have a ≤ 0.5 log10 decline in HIV-1 RNA will be discontinued from the study and will not be eligible to continue into Part 2 of the study. All participants who received placebo in Part 1 will be eligible to participate in Part 2 regardless of their viral load change. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.
This study's enrollment of 55 is below the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Females may enter the study if it is confirmed that she is:
Of childbearing potential and agrees to utilize highly effective methods or be non-heterosexually active or practice sexual abstinence from screening throughout the duration of study treatment and for 30 days following study drug dosing
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAF + their current failing ARV regimen for 10 days in Part 1
Drug: TAF · Drug: Current failing ARV regimen
Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.
Drug: TAF · Drug: Current failing ARV regimen
Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.
Drug: Placebo · Drug: Current failing ARV regimen
Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a \> 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
Drug: E/C/F/TAF · Drug: ATV
25 mg tablet administered orally once daily with food
Also known as: Vemlidy®, GS-7340
Tablets to match TAF administered orally once daily with food
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg STR administered orally once daily with food
Also known as: Genvoya®
Participants will continue taking their current ARV regimen as prescribed in Part 1.
300 mg tablet administered orally once daily.
Also known as: Reyataz®
Part 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 10
Time frame: Day 10
Part 1: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Day 10
Time frame: Baseline; Day 10
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 24
Time frame: Up to Week 24
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 48
Time frame: Up to Week 48
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 24
Time frame: Up to Week 24
Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 48
Time frame: Up to Week 48
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 24
Time frame: Baseline; Week 24
Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 48
Time frame: Baseline; Week 48
Part 2: Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline; Week 24
Part 2: Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Part 2: Change From Baseline in CD4+ Percentage at Week 24
Time frame: Baseline; Week 24
Part 2: Change From Baseline in CD4+ Percentage at Week 48
Time frame: Baseline; Week 48
Participants were enrolled at study sites in the United States, Uganda, Thailand, Russian Federation, and Dominican Republic. The first participant was screened on 25 October 2013. The last study visit occurred on 31 July 2017.
| Milestone | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Part 2 E/C/F/TAF + ATV |
|---|---|---|---|---|
| Started | 12 | 28 | 15 | 0 |
| Completed | 12 | 28 | 15 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Part 2 E/C/F/TAF + ATV |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 38 |
| Completed | 0 | 0 | 0 | 35 |
| Not completed | 0 | 0 | 0 | 3 |
| Withdrew: Enrolled in part 2 and never treated | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Unknown reason | 0 | 0 | 0 | 1 |
| percentage of participants | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo |
|---|---|---|---|
| Part 1: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10 at Day 10 | 58.3 | 60.7 | 0 |
| log10 copies/mL | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo |
|---|---|---|---|
| Part 1: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Day 10 | -0.72 ± 0.574 | -0.70 ± 0.628 | -0.04 ± 0.233 |
| percentage of participants | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 24 | 37.8 |
| percentage of participants | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Grade 3 or 4 Laboratory Abnormalities Through Week 48 | 48.6 |
| percentage of participants | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 24 | 75.7 |
| percentage of participants | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Safety of E/C/F/TAF STR Plus ATV in Participants Who Switched From a Failing Regimen as Assessed by the Percentage of Participants Experiencing Any Treatment-Emergent Adverse Event Through Week 48 | 81.1 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24 | 86.5 |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Percentage of Participants With Plasma HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48 | 97.3 |
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 24 | 94.6 |
The percentage of participants with HIV-1 RNA \< 400 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Percentage of Participants With Plasma HIV-1 RNA < 400 Copies/mL as Defined by the FDA Snapshot Analysis at Week 48 | 97.3 |
| log10 copies/mL | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 24 | -2.96 ± 0.754 |
| log10 copies/mL | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Change From Baseline in Plasma log10 HIV-1 RNA (Copies/mL) at Week 48 | -3.04 ± 0.594 |
| cells/μL | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Change From Baseline in CD4+ Cell Count at Week 24 | 76 ± 92.8 |
| cells/μL | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Change From Baseline in CD4+ Cell Count at Week 48 | 125 ± 109.0 |
| percentage change | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Change From Baseline in CD4+ Percentage at Week 24 | 4.4 ± 2.35 |
| percentage change | Part 2 E/C/F/TAF + ATV |
|---|---|
| Part 2: Change From Baseline in CD4+ Percentage at Week 48 | 5.7 ± 2.99 |
Collected over Baseline up to the last dose date plus 30 days (average exposure: Part 1 = 10 days; Part 2 = 86.5 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Sentinel Cohort TAF | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Part 1 Randomized Cohort TAF | 0/28 (0%) | 3/28 (10.7%) | 6/28 (21.4%) |
| Part 1 Randomized Cohort Placebo | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| Part 2 E/C/F/TAF + ATV | 0/37 (0%) | 4/37 (10.8%) | 26/37 (70.3%) |
| Event | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Part 2 E/C/F/TAF + ATV |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 0/12 | 1/28 | 0/15 | 0/37 |
| MyopathyMusculoskeletal and connective tissue disorders | 0/12 | 1/28 | 0/15 | 0/37 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/12 | 1/28 | 0/15 | 0/37 |
| Enlarged uvulaGastrointestinal disorders | 0/12 | 0/28 | 0/15 | 1/37 |
| HyperbilirubinaemiaHepatobiliary disorders | 0/12 | 0/28 | 0/15 | 1/37 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/12 | 0/28 | 0/15 | 1/37 |
| HypotensionVascular disorders | 0/12 | 0/28 | 0/15 | 1/37 |
| Event | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Part 2 E/C/F/TAF + ATV |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/12 | 1/28 | 0/15 | 11/37 |
| NauseaGastrointestinal disorders | 2/12 | 1/28 | 0/15 | 0/37 |
| MalariaInfections and infestations | 0/12 | 0/28 | 0/15 | 5/37 |
| HeadacheNervous system disorders | 0/12 | 0/28 | 0/15 | 4/37 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 0/28 | 0/15 | 2/37 |
| HaemorrhoidsGastrointestinal disorders | 1/12 | 0/28 | 0/15 | 0/37 |
| ProctalgiaGastrointestinal disorders | 1/12 | 0/28 | 0/15 | 0/37 |
| PyrexiaGeneral disorders | 1/12 | 0/28 | 0/15 | 2/37 |
| Oral candidiasisInfections and infestations | 1/12 | 0/28 | 0/15 | 1/37 |
| Urinary tract infectionInfections and infestations | 1/12 | 0/28 | 0/15 | 2/37 |
Full Analysis Set: participants who enrolled into Part 1 of the study and received at least one dose of study drug in Part 1.
| Age, Continuous(years) | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Total |
|---|---|---|---|---|
| Mean | 38 ± 7.3 | 40 ± 9.1 | 43 ± 8.2 | 40 ± 8.6 |
| Sex: Female, Male(Participants) | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Total |
|---|---|---|---|---|
| Female | 3 | 16 | 4 | 23 |
| Male | 9 | 12 | 11 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 0 | 1 | 6 |
| Not Hispanic or Latino | 7 | 28 | 14 | 49 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Total |
|---|---|---|---|---|
| Asian | 0 | 5 | 5 | 10 |
| Black | 3 | 22 | 9 | 34 |
| White | 4 | 1 | 0 | 5 |
| Other | 5 | 0 | 1 | 6 |
| Region of Enrollment(participants) | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Total |
|---|---|---|---|---|
| Russian Federation | 2 | 1 | 0 | 3 |
| United States | 5 | 3 | 0 | 8 |
| Dominican Republic | 5 | 0 | 1 | 6 |
| Uganda | 0 | 19 | 9 | 28 |
| Thailand | 0 | 5 | 5 | 10 |
| HIV-1 RNA(log10 copies/mL) | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Total |
|---|---|---|---|---|
| Mean | 4.18 ± 0.648 | 4.16 ± 0.544 | 4.03 ± 0.953 | 4.13 ± 0.688 |
| HIV-1 RNA Category(Participants) | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Total |
|---|---|---|---|---|
| ≤ 100,000 copies/mL | 12 | 27 | 12 | 51 |
| > 100,000 to ≤ 400,000 copies/mL | 0 | 1 | 3 | 4 |
| CD4 Cell Count(cells/µL) | Part 1 Sentinel Cohort TAF | Part 1 Randomized Cohort TAF | Part 1 Randomized Cohort Placebo | Total |
|---|---|---|---|---|
| Mean | 269 ± 207.1 | 245 ± 244.6 | 232 ± 162.4 | 246 ± 213.7 |
1 further baseline measures are reported on the registry.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
No publications or documents are linked to this record.
Ran from Oct 2013 to primary completion in May 2015, 18 months.
Results were first posted in Jun 2017, 2 years after primary completion.
Of 34 industry-sponsored phase 3 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 27. This study's 18 months is below that.
Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 19 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tenofovir alafenamide · Elvitegravir · Cobicistat · Emtricitabine · Atazanavir
Acquired Immunodeficiency Syndrome →